$9.10−0.15 (−1.67%)
Market open · 15-min delayed · as of 12:37 PM ET
Xeris Biopharma Holdings Inc · Overview
Industry: Drugs · see every company filed here →
Xeris Biopharma Holdings Inc scores 44/100. Weak. Strongest on growth, value is the soft spot, trading at 3044× earnings versus 400 Healthcare peers.
Tenet Score · vs sector
n=400Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value17
Quality61
Health18
Growth77
Factor grades
Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityCHealthFGrowthBMomentumD
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Price
Loading chart…
P/E
3,044.2×
cap ÷ fiscal 2025 net income to common
P/B
—
no P/B on file
P/S
5.8×
price to fiscal 2025 sales
ROE
—
negative equity denominator
Operating margin
8.5%
fiscal 2025, before interest and tax
Net margin
−5.1%
TTM through Jun 30, 2026
Current ratio
1.45
Jun 30, 2026 balance sheet
Net debt / EBITDA
2.7×Tenet-derived Total debt less cash and short-term investments, over EBITDA (operating income plus depreciation and amortisation) from the filed statements. Long-term investments are not counted as cash. For some companies they include marketable securities held for more than a year. Computed by Tenet from the filed statements (formula house-nde.v1), because the data vendor published no value for this year.
computed by Tenet from the filed statements
EPS CAGR 3y
—
needs five years of positive earnings
Market cap
$1.7B
small cap
Div yield
0.00%
reinvests all
52-wk range
5.25 – 11.33
low → high
Market cap: share price × the latest quarter's diluted weighted-average share count (vendor).
The whole report, at a glance · every card is a live peek, click any to open the section
Tenets
4 / 17
- ✓ Piotroski F-Score
- ~ Munger Compounders
- ~ Magic Formula
- ✕ Graham Defensive
- ✕ Quality Compounder
- ✓ Drawdown Context
+11 more →
Financials
Revenue, margins and the five-year statements.Analyst Forecasts
Consensus estimates are on the Analyst tab.
Earnings
Report dates and the beat-versus-miss record.Statistics
ROIC15%
Gross margin87%
Technical Analysis
Uptrend short-term signalvs 50-day+9.5%
vs 200-day+28.7%
RSI (14)59
News & Insights
Headlines are on the News tab.Dividends
0.00% yield
Pays no dividend. Every dollar of profit is reinvested into the business.
Ownership
59% institutional
13F flows & insider trades land here.
About Xeris Biopharma Holdings Inc
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the tre…
Composite computed 2026-10-02 · peer basis: Healthcare (n=400) · every glimpse links to its full section with sources · not investment advice.
ETF exposure
Free account: the funds that hold XERS, and at what weight. Everything else on this page stays open.Create a free account